NSCLC patient postoperative short-period recurrence metastasis risk evaluating system
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- HANGZHOU DIANZI UNIV
- Publication Date
- 2019-08-09
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to the field of artificial intelligence technology and smart medical technology, in particular to a short-term postoperative recurrence / transfer risk assessment system for NSCLC patients. Background technique
[0002] Lung cancer is one of the most common malignant tumors in the world, and it has become the first cause of death from malignant tumors in urban population in my country. Non-small cell lung cancer (NSCLC) includes squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma, and large cell carcinoma. The proportion of NSCLC patients accounts for about 80% of all lung cancer patients, and about 75% of patients are in the middle and advanced stages when they are discovered. At the same time, non-small cell lung cancer has the characteristics of high malignancy, easy recurrence and metastasis, and low five-year survival rate. Developing individualized treatment plans for NSCLC patients and timely comprehens...